Evaluation of neutrophil:lymphocyte and platelet:neutrophil ratios and their prognostic utility in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism

ObjectivesThe aim of the study was to compare the neutrophil:lymphocyte ratio (NLR) and platelet:neutrophil ratio (PNR) in cats with or without hypertrophic cardiomyopathy (HCM) and cardiogenic arterial thromboembolism (CATE) and to evaluate their prognostic significance in cats with HCM.MethodsHealthy cats and cats with HCM and CATE were prospectively enrolled between 2018 and 2020. Complete blood count and echocardiogram were performed. NLR and PNR were compared between cats in healthy, HCM and CATE groups. Outcome data, including cause of death, time to death and progression of HCM, were collected via review of medical record and owner interviews. Associations between time to cardiac-related mortality, NLR and PNR were analyzed using Kaplan-Meier curves and the Cox proportional hazards regression model.ResultsA total of 110 cats were enrolled, including 42 healthy cats, 57 cats with HCM (37 stage B1, 9 stage B2, 11 stage C) and 11 cats with CATE. Cats with CATE had the highest NLR (5.8, range 3.1-12.7) compared with HCM (<i>P</i> = 0.03) and healthy cats (<i>P</i> ⩽0.0001), while NLR was higher in cats with HCM (3.3, range 1.8-5.1) compared with healthy controls (<i>P</i> = 0.04). PNR was lower in cats with CATE (16.6, range 13.2-27.9) compared with healthy cats (<i>P</i> = 0.0027). Although PNR did not differ between cats in the healthy and HCM groups (<i>P</i> >0.9), HCM-affected cats with PNR below 40 had a significantly lower median survival time (1093-1185 days) compared with those with PNR above 40 (<i>P</i> = 0.03). Cats with PNR below 40 at the time of HCM diagnosis also had a significant risk (hazard ratio 9.8; <i>P</i> = 0.03) of cardiac-related mortality.Conclusions and relevancePNR is an accessible and cost-effective hematological biomarker that outperforms NLR and echocardiographic findings in cats with early subclinical HCM. Alterations in NLR and PNR in cats with HCM and CATE suggest a potential role of systemic inflammation in feline HCM.

Authors

Institutions

Publication Details

Journal
Journal of Feline Medicine and Surgery
Published
2025-10-01
DOI
https://doi.org/10.1177/1098612x251376773
Citations
2
Primary Topic
Cardiovascular Conditions and Treatments
Type
article
Field-Weighted Citation Impact
2.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of neutrophil:lymphocyte and platelet:neutrophil ratios and their prognostic utility in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism

Ronald H. L. Li, Lawrence Yoon
2 citations
Journal of Feline Medicine and Surgery
Cardiovascular Conditions and Treatments
2.72
article

Evaluation of neutrophil:lymphocyte and platelet:neutrophil ratios and their prognostic utility in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism

Ronald H. L. Li, Lawrence Yoon
article en
2 citations

Abstract

ObjectivesThe aim of the study was to compare the neutrophil:lymphocyte ratio (NLR) and platelet:neutrophil ratio (PNR) in cats with or without hypertrophic cardiomyopathy (HCM) and cardiogenic arterial thromboembolism (CATE) and to evaluate their prognostic significance in cats with HCM.MethodsHealthy cats and cats with HCM and CATE were prospectively enrolled between 2018 and 2020. Complete blood count and echocardiogram were performed. NLR and PNR were compared between cats in healthy, HCM and CATE groups. Outcome data, including cause of death, time to death and progression of HCM, were collected via review of medical record and owner interviews. Associations between time to cardiac-related mortality, NLR and PNR were analyzed using Kaplan-Meier curves and the Cox proportional hazards regression model.ResultsA total of 110 cats were enrolled, including 42 healthy cats, 57 cats with HCM (37 stage B1, 9 stage B2, 11 stage C) and 11 cats with CATE. Cats with CATE had the highest NLR (5.8, range 3.1-12.7) compared with HCM (<i>P</i> = 0.03) and healthy cats (<i>P</i> ⩽0.0001), while NLR was higher in cats with HCM (3.3, range 1.8-5.1) compared with healthy controls (<i>P</i> = 0.04). PNR was lower in cats with CATE (16.6, range 13.2-27.9) compared with healthy cats (<i>P</i> = 0.0027). Although PNR did not differ between cats in the healthy and HCM groups (<i>P</i> >0.9), HCM-affected cats with PNR below 40 had a significantly lower median survival time (1093-1185 days) compared with those with PNR above 40 (<i>P</i> = 0.03). Cats with PNR below 40 at the time of HCM diagnosis also had a significant risk (hazard ratio 9.8; <i>P</i> = 0.03) of cardiac-related mortality.Conclusions and relevancePNR is an accessible and cost-effective hematological biomarker that outperforms NLR and echocardiographic findings in cats with early subclinical HCM. Alterations in NLR and PNR in cats with HCM and CATE suggest a potential role of systemic inflammation in feline HCM.

Journal of Feline Medicine and SurgeryVol. 27(10)
North Carolina State University (US), Veterinary Medical Teaching Hospital (US), University of California, Davis (US)
Openalex Percentile: Top 8%
Cardiovascular Conditions and Treatments
2.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.